Prempro news | Breaking Prempro news

Wyeth's Q2 Profit Climbs on Drug Sales

...Bernard Poussot, head of global pharmaceutical operations, said that the low-dose Wyeth just launched ads urging women to talk to their doctors about menopause symptoms, something many stopped doing after the negative studies were released.The company repeated its recent full-year guidance for earnings of $2.80 to $2.90 per share, excluding any one-time costs.

Analysts are forecasting $2.86."If current strong business trends continue, full-year earnings are more likely to approach or exceed the upper end," Martin said.That's despite plans to increase research spending substantially in the second half of the year.Wyeth shares rose $1.05, or 2.3 percent, to $46.05 in early afternoon trading on the New York Stock Exchange, above their 52-week high of $45.76 reached earlier this month.———http://www.wyeth.com Copyright 2005 by The Associated Press.

This material may not be published, broadcast, rewritten or redistributed.

Related Articles and More Information » RELATED STORIES: » Yahoo Stock Tumbles After Q2 Profit Report » Yahoo Inc.

Second-Quarter Profit Soars » Pfizer Posts Q2 Profit on Lipitor Sales » Honeywell's Profit Falls on Tax Charge » Taser Posts Lower Q2 Profit on Weak Sales » Find More Articles ...

Prempro

News

Advertisers:

Wyeth's Q2 Profit Climbs on Drug Sales